Evolus, Inc. (NASDAQ:EOLS) Receives $21.25 Consensus PT from Brokerages

Shares of Evolus, Inc. (NASDAQ:EOLS) have been given a consensus rating of “Hold” by the five research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $21.25.

Several research firms have commented on EOLS. Wall Street Zen downgraded Evolus from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. HC Wainwright reduced their price objective on Evolus from $27.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. BTIG Research restated a “buy” rating and set a $18.00 price objective on shares of Evolus in a report on Monday, September 8th. Needham & Company LLC reaffirmed a “hold” rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evolus in a research report on Tuesday, October 14th.

Evolus Stock Down 1.1%

EOLS opened at $6.39 on Tuesday. The stock’s fifty day moving average is $6.73 and its two-hundred day moving average is $8.45. The company has a market capitalization of $413.31 million, a P/E ratio of -6.52 and a beta of 0.97. Evolus has a 52 week low of $5.71 and a 52 week high of $17.44.

Insider Buying and Selling at Evolus

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total transaction of $42,972.22. Following the sale, the chief marketing officer owned 89,949 shares of the company’s stock, valued at approximately $675,516.99. This trade represents a 5.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brady Stewart bought 30,000 shares of the company’s stock in a transaction on Friday, August 15th. The shares were bought at an average cost of $6.82 per share, for a total transaction of $204,600.00. Following the transaction, the director directly owned 88,629 shares in the company, valued at approximately $604,449.78. This represents a 51.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Evolus

Several hedge funds and other institutional investors have recently bought and sold shares of EOLS. Frazier Life Sciences Management L.P. acquired a new stake in shares of Evolus in the 2nd quarter worth $22,431,000. Soleus Capital Management L.P. boosted its position in shares of Evolus by 96.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after purchasing an additional 1,039,842 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Evolus in the 1st quarter worth $12,330,000. Pinnacle Associates Ltd. acquired a new stake in shares of Evolus in the 2nd quarter worth $6,318,000. Finally, First Light Asset Management LLC acquired a new stake in shares of Evolus in the 2nd quarter worth $4,795,000. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.